Advertisement

Journal of Gastroenterology

, Volume 45, Issue 6, pp 618–624 | Cite as

Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan

  • Michio HongoEmail author
  • Kazuma Fujimoto
  • Gastric Polyps Study Group
Original Article—Alimentary Tract

Abstract

Goal

To investigate the development of fundic gland polyp (FGP) and gastric hyperplastic polyp (HPP) during long-term proton pump inhibitor (PPI) therapy and risk factors of each polyp via patient status in a multicenter prospective study.

Background

The risk of developing FGP may increase during long-term PPI therapy. However, the association with PPI-induced hypergastrinemia is unclear. Helicobacter pylori (Hp) infection (which there is a high rate of in Japan) may influence the development of HPP.

Methods

Reflux esophagitis patients on PPI maintenance therapy were enrolled. At baseline, the presence of protruding lesion (gastric polyps) and mucosal atrophy was examined endoscopically. The serum gastrin level (SGL) and Hp infection status were noted. The patients took rabeprazole 10 mg/day for 104 weeks and endoscopy was performed at weeks 24, 52, 76, and 104 to check for newly developed FGPs and HPPs. The hazard ratios (HRs) of risk factors were calculated.

Results

191 patients were analyzed. The distribution of patients with baseline SGLs (pg/mL) of <200, ≥200 to <400, and ≥400 was 118 (61.8%), 51 (26.7%), and 22 (11.5%), respectively. 78 (40.8%) patients were Hp-positive, and gastric polyps were found in 70 (36.6%) patients. By the end of rabeprazole therapy, 26 (13.6%) and 17 (8.9%) patients had developed new FGPs and HPPs. In terms of risk factors, Hp-positive was significantly lower (HR = 0.288; 95% CI, 0.108–0.764) for FGP while SGL ≥400 pg/mL was significantly higher (HR = 4.923; 95% CI, 1.486–16.31) for HPP.

Conclusion

During long-term PPI therapy, FGP development was associated with absence of Hp infection. Meanwhile, Hp infection and high SGL may influence HPP development.

Keywords

Fundic gland polyp Hyperplastic polyp Long-term proton pump inhibitor therapy 

Notes

Acknowledgments

This study was funded by Eisai Co., Ltd., Tokyo, Japan. We would like to thank Dr. Jun Miwa and Dr. Tomoki Inaba for providing the endoscopic and histological images of polyps. We also would like to thank five staff of Eisai Co., Ltd. (Yasuhiro Marukawa, Toshihisa Arai, Kazutaka Matsuo, Toshiyuki Tamai, and Yukinori Sakata) for their kind assistance in preparing the manuscript.

References

  1. 1.
    Stolte M, Sticht T, Eidt S, Ebert D, Finkenzeller G. Frequency, location, and age and sex distribution of various types of gastric polyp. Endoscopy. 1994;26:659–65.CrossRefPubMedGoogle Scholar
  2. 2.
    Borch K, Skarsgård J, Franzén L, Mårdh S, Rehfeld JF. Benign gastric polyps: morphological and functional origin. Dig Dis Sci. 2003;48:1292–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Uemura N. Gastric adenoma, hyperplastic polyp and fundic gland polyp. Nippon Rinsho. 2005;63(Suppl 11):560–4. in Japanese.PubMedGoogle Scholar
  4. 4.
    Oberhuber G, Stolte M. Gastric polyps: an update of their pathology and biological significance. Virchows Arch. 2000;437:581–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Haruma K, Sumii K, Yoshihara M, Watanabe C, Kajiyama G. Gastric mucosa in female patients with fundic glandular polyps. J Clin Gastroenterol. 1991;13:565–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Dickey W, Kenny BD, McConnell JB. Prevalence of fundic gland polyps in a western European population. J Clin Gastroenterol. 1996;23:73–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Sakai N, Tatsuta M, Hirasawa R, Iishi H, Baba M, Yokota Y, et al. Low prevalence of Helicobacter pylori infection in patients with hamartomatous fundic polyps. Dig Dis Sci. 1998;43:766–72.CrossRefPubMedGoogle Scholar
  8. 8.
    Jalving M, Koornstra JJ, Wesseling J, Boezen HM DE, Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1341–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Jain R, Chetty R. Gastric hyperplastic polyps: a review. Dig Dis Sci. 2009;54:1839–46.CrossRefPubMedGoogle Scholar
  10. 10.
    Abraham SC, Singh VK, Yardley JH, Wu TT. Hyperplastic polyps of the stomach: associations with histologic patterns of gastritis and gastric atrophy. Am J Surg Pathol. 2001;25:500–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Haruma K, Yoshihara M, Sumii K, Tari A, Watanabe C, Kodoi A, et al. Gastric acid secretion, serum pepsinogen I, and serum gastrin in Japanese with gastric hyperplastic polyps or polypoid-type early gastric carcinoma. Scand J Gastroenterol. 1993;28:633–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Daibo M, Itabashi M, Hirota T. Malignant transformation of gastric hyperplastic polyps. Am J Gastroenterol. 1987;82:1016–25.PubMedGoogle Scholar
  13. 13.
    Ji F, Wang ZW, Ning JW, Wang QY, Chen JY, Li YM. Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. World J Gastroenterol. 2006;12:1770–3.PubMedGoogle Scholar
  14. 14.
    Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1:87–97.CrossRefGoogle Scholar
  15. 15.
    Satoh K, Kimura K, Taniguchi Y, Kihira K, Takimoto T, Saifuku K, et al. Biopsy sites suitable for diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol. 1998;93:569–73.CrossRefPubMedGoogle Scholar
  16. 16.
    Mihara M, Haruma K, Kamada T, Komoto K, Yoshihara M, Sumii K, et al. The role of endoscopic findings for the diagnosis of Helicobacter pylori infection: evaluation in a country with high prevalence of atrophic gastritis. Helicobacter. 1999;4:40–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Graham JR. Omeprazole and gastric polyposis in humans [letter]. Gastroenterology. 1993;104:1584.PubMedGoogle Scholar
  18. 18.
    Mogadam M, Houk RR. Long-term use of omeprazole is associated with development of benign epithelial gastric polyps [abstract]. Am J Gastroenterol. 1996;91:A151.Google Scholar
  19. 19.
    Reekmans A, Serge N, Reynaert H, et al. Fundic gland polyps and chronic PPI treatment: a prospective study [abstract]. Gastroenterology. 2001;120:A244.Google Scholar
  20. 20.
    Kinoshita Y, Tojo M, Yano T, Kitajima N, Itoh T, Nishiyama K, et al. Incidence of fundic gland polyps in patients without familial adenomatous polyposis. Gastrointest Endosc. 1993;39:161–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Carmack SW, Genta RM, Schuler CM, et al. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol. 2009;104:1524–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Genta RM, Schuler CM, Robiou CI, et al. No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study over 100,000 patients. Clin Gastroenterol Hepatol. 2009;7:849–54.CrossRefPubMedGoogle Scholar
  23. 23.
    Yamamoto A, Ishiguro H, Kondo T, Naruse S, Goto H. Low prevalence of Helicobacter pylori infection in patients with fundic gland polyps. Nippon Rinsho. 2005;63(Suppl 11):621–4.PubMedGoogle Scholar
  24. 24.
    Shand AG, Taylor AC, Banerjee M, Lessels A, Coia J, Clark C, et al. Gastric fundic gland polyps in south-east Scotland: absence of adenomatous polyposis coli gene mutations and a strikingly low prevalence of Helicobacter pylori infection. J Gastroenterol Hepatol. 2002;17:1161–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Watanabe N, Seno H, Nakajima T, Yazumi S, Miyamoto S, Matsumoto S, et al. Regression of fundic gland polyps following acquisition of Helicobacter pylori. Gut. 2002;51:742–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Declich P, Tavani E, Bellone S, Porcellati M, Pastori L, Omazzi B, et al. Sporadic fundic gland polyps: what happened before? [letter]. Gut. 2004;53:1721.PubMedGoogle Scholar
  27. 27.
    Fossmark R, Jianu CS, Martinsen TC, et al. Fundic gland polyps induced by proton pump inhibition are not related to the level of hypergastrinemia and serum Chromogranin A is affected by meals [abstract]. Gastroenterology. 2007;132(Suppl 2):A407.Google Scholar
  28. 28.
    Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol. 1998;110:615–21.PubMedGoogle Scholar
  29. 29.
    Collins S, Tydd T. Gastric polyps and long-term omeprazole [abstract]. J Gastroenterol Hepatol. 1998;13:A149.Google Scholar
  30. 30.
    Ohkusa T, Takashimizu I, Fujiki K, Suzuki S, Shimoi K, Horiuchi T, et al. Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized clinical trial. Ann Intern Med. 1998;129:712–5.Google Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Michio Hongo
    • 1
    Email author
  • Kazuma Fujimoto
    • 2
  • Gastric Polyps Study Group
  1. 1.Departments of Comprehensive Medicine and Psychosomatic MedicineTohoku University HospitalSendaiJapan
  2. 2.Department of Internal MedicineSaga Medical SchoolSagaJapan

Personalised recommendations